<- Go Home
Vaccinogen, Inc.
Vaccinogen, Inc., a biotechnology company, focuses on the development and commercialization of cancer vaccines and immunotherapeutic products for cancers in the United States. It primarily offers OncoVAX, a cancer vaccine for the post-surgical treatment of Stage II colon cancer. The company was founded in 2007 and is headquartered in Baltimore, Maryland.
Market Cap
$3.7K
Volume
8.1K
Cash and Equivalents
$445.8K
EBITDA
-$21.8M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$0.00
52 Week Low
$0.00
Dividend
N/A
Price / Book Value
0.00
Price / Earnings
-0.00
Price / Tangible Book Value
-0.00
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$28.6M
Return on Equity
60.68%
Return on Assets
-29.51
Cash and Short Term Investments
$445.8K
Debt
$3.8M
Equity
$39.7M
Revenue
N/A
Unlevered FCF
-$3.0M
Sector
Biotechnology
Category
N/A